As the threat of resistance to current malaria treatments grows Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase III development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum
Riamet is indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults, children and infants of 5 kg and above. Consideration should be given to official guidance regarding the appropriate use of antimalarial agents.
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF 156, a next-generation antimalarial compound with...
Background: The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine.
For the treatment of chloroquine resistant falciparum malaria in adults and children aged 5 years or older (and ≥ 20kg) Treatment and prevention of nocturnal leg cramps in adults and the elderly, when cramps cause regular disruption of sleep (see section 4.2 and Section 4.4).
For the treatment of falciparum malaria Treatment and prevention of nocturnal leg cramps in adults and the elderly, when cramps cause regular disruption of sleep (see section 4.2 and Section 4.4)
Aims: The LION-HEART study was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure.
Teva Pharmaceutical Industries Ltd. announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult...